Comment on "Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women:: survival analysis and updated safety results" By J.-M.!Nabholtz et al.

被引：1

作者：

Mouridsen, HT ^{[1
]}

Chaudri-Ross, HA

机构：

[1] Rigshosp, DK-2100 Copenhagen, Denmark

[2] Novartis Pharma AG, Clin Res & Dev, Basel, Switzerland

来源：

EUROPEAN JOURNAL OF CANCER | 2004年 / 40卷 / 07期

关键词：

D O I：

10.1016/j.ejca.2003.09.040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1095 / 1096

页数：2

共 23 条

[1] Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results
Nabholtz, JM
Bonneterre, J
Buzdar, A
Robertson, JFR
Thürlimann, B
EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) : 1684 - 1689
[2] Reply to comment on "Anastrozole (Arimidex ™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results" by H.T.!Mouridsen, H.A.!Chaudri-Ross
Nabholtz, JM
EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) : 1097 - 1097
[3] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
Bonneterre, J
Thürlimann, B
Robertson, JFR
Krzakowski, M
Mauriac, L
Koralewski, P
Vergote, I
Webster, A
Steinberg, M
von Euler, M
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
[4] Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Vergote, I
Bonneterre, J
Thürlimann, B
Robertson, J
Krzakowski, M
Mauriac, L
Koralewski, L
Webster, A
Steinberg, M
von Euler, M
EUROPEAN JOURNAL OF CANCER, 2000, 36 : S84 - S85
[5] Anastrozole (Arimidex™) versus tamoxifen as 1st-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women -: Combined analysis from two identically designed multicenter trials
Robertson, JFR
BRITISH JOURNAL OF CANCER, 2000, 83 : 39 - 39
[6] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
Simons, WR
Jones, D
Buzdar, A
CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
[7] Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study (vol 18, pg 3748, 2000)
Vergote, I
Bonneterre, J.
Thuerlimann, B.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 343 - 343
[8] Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women:: Findings highlight the importance of receptor status assessment prior to treatment initiation.
Buzdar, A
Bonneterre, J
Nabholtz, JM
Robertson, JFR
Thürlimann, B
von Euler, M
Steinberg, M
Webster, A
ANNALS OF ONCOLOGY, 2000, 11 : 25 - 25
[9] Anastrozole ('arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind crossover SAKK Trial 21/95 - a sub-study of Anastrozole Trial 0027.
Thuerlimann, B
Hess, D
Koeberle, D
Senn, I
Ballabeni, P
Pagani, O
Perey, L
Aebi, S
Rochlitz, C
Goldhirsch, A
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S73 - S73
[10] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
Simons, R
Bassi, R
Jones, D
Barrett-Lee, P
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68

← 1 2 3 →